Tuesday, 6 October 2015
Last updated 20 hours ago
May 14 2014 | 12:16pm ET
Pershing Square Capital Management is looking to its fellow Allergan Inc. shareholders to pressure the Botox-maker to negotiate with Valeant Pharmaceuticals International, whose $46 billion takeover offer it rejected on Monday.
The New York-based hedge fund yesterday disclosed that it demanded a list of registered shareholders from Allergan, with plans to hold a referendum on whether the company should speak with potential buyers. Pershing Square chief William Ackman told The Wall Street Journal that the non-binding poll would give “shareholders an opportunity to express their point of view. What could be more democratic than that?”
The unusual maneuver, taken instead of seeking to force a special meeting, helps Pershing Square sidestep Allergan’s poison pill, which not only blocks the hedge fund from increasing its 9.7% stake, but also limits its communications with shareholders. Proxy campaigns are excluded from the restrictions.
The referendum also keeps Pershing Square in control of the process; if a special meeting were called, Allergan would have up to four months to schedule it.
Allergan, which called Valeant’s Pershing Square-backed offer too low, and which said it prefers to remain independent, said that the referendum was a “self-serving enterprise” that allows Valeant and the hedge fund to dictate “their own process.”
Valeant also made clear that it wasn’t giving up, saying it would improve its cash-and-stock offer on May 28. It is unclear whether the company will make a higher offer or increase the amount of cash in the deal, in an effort to entice Allergan to the negotiating table.
May 27 2015 | 2:15pm ET
Support Hedge Funds Care, also known as Help For Children (HFC), by participating in this year's raffle. All proceeds go to support HFC's mission of preventing and treating child abuse. Read more…